Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone XR Extension in Alzheimer's Disease
NCT00550420Phase 3Terminated
- Sponsor
- GSK
- Start
- Oct 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of rosiglitazone in Alzheimer's disease (AD), sponsored by GSK. Started Oct 2007; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00550420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00550420.